Principal Financial Group Inc. Purchases 3,668 Shares of LivaNova PLC (NASDAQ:LIVN)

Principal Financial Group Inc. lifted its position in LivaNova PLC (NASDAQ:LIVN) by 2.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 179,546 shares of the company’s stock after buying an additional 3,668 shares during the period. Principal Financial Group Inc. owned about 0.33% of LivaNova worth $7,053,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. PNC Financial Services Group Inc. lifted its stake in shares of LivaNova by 29.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company’s stock worth $292,000 after buying an additional 1,424 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of LivaNova by 2,299.7% in the first quarter. GAMMA Investing LLC now owns 8,759 shares of the company’s stock worth $344,000 after buying an additional 8,394 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new position in shares of LivaNova in the fourth quarter worth approximately $2,772,000. Envestnet Asset Management Inc. lifted its stake in shares of LivaNova by 15.4% in the fourth quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company’s stock worth $2,034,000 after buying an additional 5,850 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC lifted its position in LivaNova by 147.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 98,940 shares of the company’s stock valued at $4,582,000 after purchasing an additional 58,911 shares during the period. Institutional investors own 97.64% of the company’s stock.

LivaNova Stock Down 1.2%

Shares of LIVN stock opened at $43.43 on Wednesday. LivaNova PLC has a 12 month low of $32.48 and a 12 month high of $57.35. The stock has a market cap of $2.37 billion, a P/E ratio of -10.62 and a beta of 0.90. The company has a current ratio of 1.58, a quick ratio of 1.37 and a debt-to-equity ratio of 0.53. The company has a 50 day simple moving average of $44.85 and a two-hundred day simple moving average of $43.23.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Wolfe Research upgraded shares of LivaNova from a “peer perform” rating to an “outperform” rating and set a $60.00 price objective on the stock in a research report on Tuesday, May 20th. Wall Street Zen downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 8th. Needham & Company LLC restated a “buy” rating and set a $64.00 price objective on shares of LivaNova in a research report on Tuesday, May 13th. Barclays lowered their price objective on shares of LivaNova from $56.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Thursday, May 8th. Finally, Robert W. Baird increased their price objective on shares of LivaNova from $55.00 to $61.00 and gave the company an “outperform” rating in a research report on Thursday, May 8th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $59.29.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.